Biochemical Pharmacology volume 80, issue 5, P575-583 2010 DOI: 10.1016/j.bcp.2010.04.006 View full text
|
|
Share
Stefan Duensing, Anette Duensing

Abstract: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract and are caused by activating KIT or PDGFRA mutations. GISTs can be successfully treated with the small molecule kinase inhibitor imatinib mesylate (Gleevec, Novartis) with response rates of up to 85%. However, complete responses are rare, and most patients will develop imatinib resistance over time. Recent results have shown that although imatinib effectively stimulates apoptotic cell death in sens…

expand abstract